| Patents for A61P 25 - Drugs for disorders of the nervous system (183,225) |
|---|
| 11/17/2005 | WO2004096208A9 Composition for oral administration containing alkylene dioxybenzene derivative |
| 11/17/2005 | WO2004074281A8 Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs |
| 11/17/2005 | US20050256333 4-(3-(2,6-Dimethoxybenzyloxy)phenyl)-4-oxobutyric acid or derivatives for treatment of insulin resistance syndrome, diabetes, cachexia, hyperlipidemia, fatty liver disease, obesity, atherosclerosis or arteriosclerosis |
| 11/17/2005 | US20050256326 Process for decreasing environmental pollutants in an oil or a fat, a volatile environmental pollutants decreasing working fluid, a health supplement, and an animal feed product |
| 11/17/2005 | US20050256315 1h-benzo{f}indazol-5-yl derivatives as selective glucocorticoid receptor modulators |
| 11/17/2005 | US20050256302 Novel peptides having camp producing activity |
| 11/17/2005 | US20050256207 Methods for modulating macrophage proliferation in ocular disease using polyamine analogs |
| 11/17/2005 | US20050256205 prepared by dissolving Venlafaxine in an organic solvent to form a solution at elevated temperature, adding seeding crystals, cooling the solution, and separating the crystalline polymorph; storage stability |
| 11/17/2005 | US20050256201 Phenethanolamine derivatives |
| 11/17/2005 | US20050256194 Denaturants for sympathomimetic amine salts |
| 11/17/2005 | US20050256180 drugs such as 1 -[4-(aminosulfonyl)phenyl]-8-{[(trifluoromethyl)sulfonyl]amino}-4,5-dihydro-1H-benzo[g]indazole-3-carboxamide, used as antiinflammatory agents, antiarthritic agents, antipyretics or analgesics |
| 11/17/2005 | US20050256167 Preparation and use of imidazole derivatives for treatment of obesity |
| 11/17/2005 | US20050256160 Beta-alanine derivatives and the use thereof |
| 11/17/2005 | US20050256155 e.g. (3S,4aR,6R,8aR)-6-[2-(1H-Tetrazol-5-yl)-ethyl]-1,2,3,4,4a,5,6,7,8,8a-decahydro-isoquinoline-3-carboxylic acid 2-ethyl-butyl ester trifluoroacetate salt; are substantially converted to the parent monoacid in the patient; AMPA glutamate receptor antagonists |
| 11/17/2005 | US20050256147 Neuroprotective properties of dextrorotatory morphinans |
| 11/17/2005 | US20050256146 Alpha-7 nicotinic receptor agonists and stains in combination |
| 11/17/2005 | US20050256142 New purine derivatives |
| 11/17/2005 | US20050256131 Pharmaceutical active substance combination and the use thereof |
| 11/17/2005 | US20050256122 Substituted pyridazinones |
| 11/17/2005 | US20050256119 selective serotonine (5-HT) reuptake inhibitor activity in combination with additional alpha 2-adrenocptor antagonist activity; To treat anxiety, movement disorders, psychosis, Parkinson's disease and body weight disorders including anorexia nervosa and bulimia without being sedative |
| 11/17/2005 | US20050256117 Ophthalmic compositions for treating ocular hypertension |
| 11/17/2005 | US20050256112 Enhancing the serotonergic neurotransmission; side effects reduction; nervous system disorders; sexual disorders; analgesics; antidepressants; anticancer; anxiolytic agents; neurodegenerative diseases; gastrointestinal tract disorders; eating disorders |
| 11/17/2005 | US20050256108 avoid the adverse side effects associated with non-selective receptor interactions; 1-(4-Fluorobenzyl)-2-(4-methoxybenzyl)-8-methyl-1,2,8-triaza-spiro[4.5]decan-3-one; 1-oxa-4,9-diaza-spiro[5.5]undecan-3-one compounds as monoamine receptor modulators; schizophrenia, psychosis, migraine, hypertension |
| 11/17/2005 | US20050256106 Such as 1-phenylsulfonyl-4-piperazinylindole hydrochloride for treatment or prophylaxis of disease mediated by serotonin related receptor, obesity, and/or central nervous system disorder |
| 11/17/2005 | US20050256098 CGRP receptor antagonists |
| 11/17/2005 | US20050256066 Fredericamycin derivatives |
| 11/17/2005 | US20050256051 Nuclear receptor-mediated introduction of a PNA into cell nuclei |
| 11/17/2005 | US20050256031 Composition for relieving discomfort |
| 11/17/2005 | US20050255593 Bone marrow stromal cell-derived schwann cells |
| 11/17/2005 | US20050255576 PGDS inhibitor; antiallergies, sleep control, antiobesity and brain wound healing; Crystals of a complex of human origin hematopoietic prostaglandin D synthase, glutathione and a substrate analog or an inhibitor |
| 11/17/2005 | US20050255549 IRAK-4: compositions and methods of use |
| 11/17/2005 | US20050255529 Diagnostics and therapeutics for diseases associated with a new human 5-ht6 receptor |
| 11/17/2005 | US20050255518 Methods and compositions for the treatment and diagnosis of pain disorders using 46566 |
| 11/17/2005 | US20050255168 Cerebral protection with a gas comprising xenon |
| 11/17/2005 | US20050255156 Reverse-micellar delivery system for controlled transportation and enhanced absorption of agents |
| 11/17/2005 | US20050255113 Methods and compositions for inhibiting polypeptide accumulation associated with neurological disorders |
| 11/17/2005 | US20050255095 Destruction of prions using vibrolysin or variants thereof |
| 11/17/2005 | US20050255093 treating nervous system disorders induced by stroke or injury, injured by trauma to reduce oxidative stress, administering a conjugate of antioxidant enzyme and a clostridial neurotoxin cell binding domain, and a clostridial neurotoxin translocation domain; tissue-targeted therapy |
| 11/17/2005 | DE102004019736A1 Use of a calcitonin gene related peptide antagonist and a serotonin reuptake inhibitor to treat headaches, migraine and cluster headaches |
| 11/17/2005 | CA2566426A1 Indol-2-one derivatives for the treatment of central nervous disorders, gastrointestinal disorders and cardiovascular disorders |
| 11/17/2005 | CA2566398A1 Use of opioid receptor antagonist compounds for the prevention and/or treatment of diseases associated with the target calcineurin |
| 11/17/2005 | CA2566228A1 Method of tonic treatment with oxyphenbutazone derivatives |
| 11/17/2005 | CA2566184A1 Imidazopyridine compound |
| 11/17/2005 | CA2566096A1 Piperazine derivatives of alkyl oxindoles |
| 11/17/2005 | CA2566092A1 Crystalline forms of duloxetine free base |
| 11/17/2005 | CA2565996A1 Combination of atypical antipsychotics and 5-ht1b receptor antagonists |
| 11/17/2005 | CA2565731A1 Analog compounds of analgesic peptides derived from the venom of crotalus durissus terrificus snakes, their uses, compositions, methods of preparation and purification |
| 11/17/2005 | CA2565214A1 (4, 5, 6, 7-tetrahydro-1-h-indol-7-yl) acetic acid derivatives for treatment of alzheimer's disease |
| 11/17/2005 | CA2565061A1 Pyridine derivatives of alkyl oxindoles as 5-ht7 receptor active agents |
| 11/17/2005 | CA2564068A1 Use of (4-alkylpiperazinyl) (phenyl) methanones in the treatment of alzheimer's disease |
| 11/17/2005 | CA2564009A1 Piperazine derivatives of alkyl oxindoles |
| 11/17/2005 | CA2560264A1 Gm1 promoter and use thereof |
| 11/17/2005 | CA2558113A1 Transdermal iontophoretic delivery of piperazinyl-2(3h)-benzoxazolone compounds |
| 11/16/2005 | EP1595871A2 Metabotropic glutamate receptor antagonists and their use for treating central nervous system diseases |
| 11/16/2005 | EP1595867A1 Melanin-concentrating hormone receptor antagonists containing piperidine derivatives as the active ingredient |
| 11/16/2005 | EP1595543A2 Antineoplastic pharmaceutical compositions comprising taurolidine or taurultam and 5-fluorouracil |
| 11/16/2005 | EP1595542A1 Transdermal iontophoretic delivery of piperazinyl-2(3H)-benzoxazolone compounds |
| 11/16/2005 | EP1594969A2 Active immunization to generate antibodies to soluble a-beta |
| 11/16/2005 | EP1594872A1 Cannabinoid receptor ligands and uses thereof |
| 11/16/2005 | EP1594868A1 8-aza-bicyclo (3.2.1) octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| 11/16/2005 | EP1594864A1 Benzofuran oxyethylamines serving as antidepressant drugs and anxiolytic drugs |
| 11/16/2005 | EP1594861A1 Triazole compounds and the therapeutic use thereof |
| 11/16/2005 | EP1594856A1 Cb 1/cb 2 receptor ligands and their use in the treatment of pain |
| 11/16/2005 | EP1594848A1 Aryl acid pyrimidinyl methyl amides, pyridazinyl methyl amides and related compounds |
| 11/16/2005 | EP1594841A1 Vegfr-2 and vegfr-3 inhibitory anthranylamidopyridines |
| 11/16/2005 | EP1594840A1 Piperidine-benzenesulfonamide derivatives |
| 11/16/2005 | EP1594836A1 Hydroxy-tetrahydro-naphthalenylurea derivatives |
| 11/16/2005 | EP1594833A1 1-phenylalkanecarboxylic acid derivatives for the treatment of neurodegenerative diseases |
| 11/16/2005 | EP1594506A1 Benzo (1,2,5) thiadiazole als crf-antagonisten |
| 11/16/2005 | EP1594492A2 Novel inhibitors of formation of advanced glycation endproducts (ages) |
| 11/16/2005 | EP1594467A1 Abuse-deterrent pharmaceutical compositions of opioids and other drugs |
| 11/16/2005 | EP1594441A2 Method for treating pain by administering a nerve growth factor antagonist and an nsaid and composition containing the same |
| 11/16/2005 | EP1594436A2 Polymer conjugates of mutated neublastin |
| 11/16/2005 | EP1492795B1 1- or 3-thia-benzonaphthoazulenes as inhibitors of tumour necrosis factor production and intermediates for the preparation thereof |
| 11/16/2005 | EP1487472A4 Stabilization of hypoxia inducible factor (hif) alpha |
| 11/16/2005 | EP1463823A4 Methods of increasing endogenous erythropoietin (epo) |
| 11/16/2005 | EP1409488B1 Imidazo-triazine derivatives as ligands for gaba receptors |
| 11/16/2005 | EP1397129B1 Heteroaryloxy 3-substituted propanamines s serotonin and norepinephrine reuptake inhibitors |
| 11/16/2005 | EP1379516B1 Alkoxycarbonylamino benzoic acid or alkoxycarbonylamino tetrazolyl phenyl derivatives as ip antagonists |
| 11/16/2005 | EP1363631A4 Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| 11/16/2005 | EP1363608B1 Formulations comprising ibuprofen and diphenhydramine and the use thereof for the treatment of sleep disturbances |
| 11/16/2005 | EP1347982B1 Spiro isobenzofuran-1,4'-piperidin]-3-ones and 3h-spiroisobenzofuran-1,4'-piperidines |
| 11/16/2005 | EP1317426B1 Beta-thio-amino acids |
| 11/16/2005 | EP1289517B1 Pharmaceutical compositions comprising cannabidiol derivatives |
| 11/16/2005 | EP1222191B1 Benzodiazepin derivatives, the production and use thereof |
| 11/16/2005 | EP1218374B1 Pharmaceutically active sulfonamide derivatives |
| 11/16/2005 | EP1049479B1 Analgesic from snake venom |
| 11/16/2005 | EP0970211B1 Variants of ciliary neurotrophic factor with enhanced receptor selectivity and method for their selection |
| 11/16/2005 | EP0923370B1 Acetyl choline esterase inhibitors for treating and diagnosing sleep disordered breathing |
| 11/16/2005 | EP0876395B1 Inhibitors of interleukin-1beta converting enzyme |
| 11/16/2005 | EP0873406B1 Protein induced by deprenyl |
| 11/16/2005 | EP0766538B1 Subcutaneous implant |
| 11/16/2005 | CN1697879A Biomolecule transfer method using virus envelope and composition and system therefor |
| 11/16/2005 | CN1697878A Novel peptides having cAMP producing activity |
| 11/16/2005 | CN1697836A Substituted 5,6,6a,11b-tetrahydro-7-oxa-5-aza-benzo[c]fluorene-6-carboxylic acid compounds as NMDA-antagonists |
| 11/16/2005 | CN1697833A Preparation of cis-fused 3,3a,8,12b-tetrahydro-2-h-dibenzo[3,4:6,7]cyclohepta[1,2-b]furan derivatives |
| 11/16/2005 | CN1697830A 嘧啶衍生物 Pyrimidine derivatives |
| 11/16/2005 | CN1697828A New compounds and their use in medicine, process for their preparation and pharmaceutical compositions containing them |
| 11/16/2005 | CN1697656A Phentanyl-containing adhesive patch for application to oral-cavity mucosa |
| 11/16/2005 | CN1697655A Methods and compositions using immunomodulatory compounds for treatment and management of cancers and other diseases |